Researchers at the University of Barcelona are participating in a new consortium to design a drug with an innovative approach against this disease, which could also be used to treat other hereditary r...
Read moreEn la investigación se explica la interacción entre el gen FAS, la proteína mTOR durante la maduración extrafolicular en células B humanas y su implicación en el desarrollo del síndrome linfopr...
Read moreDos recientes estudios ofrecen importantes avances en la utilización de terapia génica como tratamiento para la pérdida auditiva.
Read moreVivet Therapeutics announces the financing of EUR 4.9 million received from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX)...
Read moreWith this latest acquisition of 1 GHz equipment, the CIC bioGUNE NMR facilities are now among the most advanced in southern Europe, highlighting the capacity of the research centre to lead research in...
Read moreEl grupo ‘Bases Moleculares de los Sistemas Biológicos’ de la Universidad de Málaga (SIBIUMA) forma parte del proyecto internacional ‘EURAS’, que avanza en el estudio de las RASopatías, uno...
Read moreIniciará su actividad a finales de 2025 y se convertirá, junto al Hospital Sant Joan de Déu Barcelona, en uno de los mayores campus del mundo dedicados a las enfermedades raras.
Read moreIn an international study, they propose optimizing the design of clinical trials in rare tumors to speed up the study and approval of new drugs that will make it possible to respond to patients with t...
Read moreApproximately 80% of RRDs are genetic in origin, while the remaining 20% are the result of infectious, immunological, degenerative or proliferative diseases. The most important problem faced by patien...
Read moreIn the fight against these diseases, at IRB Barcelona, they are committed to interdisciplinary research through new projects aimed at better understanding rare diseases and developing new therapies an...
Read moreThe Nucleic Acids Chemistry group, led by Prof. Ramon Eritja’s of the IQAC (CSIC), is participating in a multidisciplinary network for Myotonic Dystrophy Type 1 (DM1) with other 6 research groups...
Read moreThe Orphan Drug Designation indicates the acknowledgement by the Regulatory Authorities of USA and the EU that PBF-999 have the potential to address the specific needs of individuals suffering from Pr...
Read more